Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 18/20 | 0.51 |
| ▸ | MAPK10 | P53779 | 2/20 | 0.51 |
| ▸ | EGFR | P00533 | 1/20 | 0.48 |
| ▸ | RAF1 | P04049 | 1/20 | 0.48 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.48 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.48 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.48 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.48 |
| ▸ | GSK3B | P49841 | 1/20 | 0.48 |
| ▸ | CSNK1D | P48730 | 3/20 | 0.46 |
| ▸ | CSNK1E | P49674 | 2/20 | 0.46 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.46 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.46 |
| ▸ | MAPK13 | O15264 | 2/20 | 0.46 |
| ▸ | MAPK12 | P53778 | 2/20 | 0.46 |
| ▸ | MAPK11 | Q15759 | 2/20 | 0.46 |
| ▸ | SRC | P12931 | 2/20 | 0.45 |
| ▸ | BRAF | P15056 | 2/20 | 0.45 |
| ▸ | KDR | P35968 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4408284 | 0.77 | MAPK14 (0.58) | MAPK14MAPK10EGFRRAF1ADORA3 | |
| SCHEMBL4409918 | 0.75 | MAPK14 (0.48) | MAPK14MAPK10EGFRRAF1ADORA3 | |
| SCHEMBL4412139 | 0.75 | MAPK14 (0.48) | MAPK14MAPK10EGFRRAF1ADORA3 | |
| SCHEMBL4408472 | 0.75 | MAPK14 (0.48) | MAPK14MAPK10EGFRRAF1ADORA3 | |
| SCHEMBL4410172 | 0.74 | MAPK14 (0.47) | MAPK14MAPK10CSNK1DCSNK1ECSNK1A1 | |
| SCHEMBL4408115 | 0.74 | MAPK14 (0.47) | MAPK14MAPK10CSNK1DMAPK13MAPK12 | |
| SCHEMBL5497318 | 0.73 | MAPK14 (0.43) | MAPK14MAPK10EGFRRAF1ADORA3 | |
| SCHEMBL4410204 | 0.73 | MAPK14 (0.46) | MAPK14MAPK10CSNK1DCSNK1ECSNK1A1 | |
| SCHEMBL4409114 | 0.71 | HTR3A (0.47) | MAPK14MAPK10GSK3BMAPK13MAPK12 | |
| SCHEMBL4408106 | 0.70 | MAPK14 (0.44) | MAPK14MAPK10CSNK1DCSNK1ECSNK1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090264446-A9 | Condensed Pyridines as Kinase Inhibitors | PALAU PHARMA, S.A. (ES) | 2009-10-22 | — | — | US | claimed |
| US-20080318977-A1 | Condensed Pyridines as Kinase Inhibitors | PALAU PHARMA, S.A. (ES) | 2008-12-25 | — | — | US | claimed |
| US-20090264446-A9 | Condensed Pyridines as Kinase Inhibitors | PALAU PHARMA, S.A. (ES) | 2009-10-22 | — | — | US | disclosed |
| US-20080318977-A1 | Condensed Pyridines as Kinase Inhibitors | PALAU PHARMA, S.A. (ES) | 2008-12-25 | — | — | US | disclosed |
| EP-1833828-A2 | CONDENSED PYRIDINES AS KINASE INHIBITORS | Palau Pharma, S.A. (ES) | 2007-09-19 | — | — | EP | disclosed |
| WO-2006013095-A2 | CONDENSED PYRIDINES AS KINASE INHIBITORS | PALAU PHARMA, S.A. (ES) | 2006-02-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090264446-A9 | Condensed Pyridines as Kinase Inhibitors | MAPK1, MAP4K2, MAP3K1 | MAPK14 36/4885MAPK10 34/4885EGFR 1270/4885 |
| US-20080318977-A1 | Condensed Pyridines as Kinase Inhibitors | MAPK1, MAP4K2, MAP3K1 | MAPK14 36/4885MAPK10 34/4885EGFR 1270/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.